EMEIS : The downward trend should continue
Entry price | Target | Stop-loss | Potential |
---|
€33.36 |
€24.6 |
€41.9 |
+26.26% |
---|
The declining trend in the stock price that has been seen for a number of trading sessions, should not be expected to reach a turning point over the coming days.
Strengths● The company's attractive earnings multiples are brought to light by a P/E ratio at 9.16 for the current year.
● The company's share price in relation to its net book value makes it look relatively cheap.
● The company has a low valuation given the cash flows generated by its activity.
● The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses● The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
● The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
● The overall consensus opinion of analysts has deteriorated sharply over the past four months.
● Over the past twelve months, analysts' opinions have been revised negatively.
● The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
● Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.